Summary of Study ST000530
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000389. The data can be accessed directly via it's Project DOI: 10.21228/M8S02S This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST000530 |
Study Title | Effects of herb DG and KK01 on Type 2 Diabetes Mellitus (T2DM) through Lipidomics |
Study Type | LC-MS lipidomics |
Study Summary | According to the results in animal test, KK01 is effective in controlling blood glucose increase with comparable effect as metformin and rosiglitazone. This study will conduct lipid profile comparison for serum samples generated from the animal tests. The comparison will be based on the following groups: 1) db/db mice + DG-high dose; 2) db/db mice +DG-low dose; 3) db/db mice + KK01-high dose; 4) db/db mice + KK01-low dose; 5) db/db mice + metformin; 6) db/db mice + rosiglitazone; 7) db/db mice + saline (disease model); and 8) wild type mice + saline (healthy model). The determined lipid marker(s) will be applied to elucidate the drug target(s) and mechanisms of DG and KK01. Furthermore, comparison of target(s) between KK01 and the first line drugs in diabetic treatment, e.g., metformin and rosiglitazone, will facilitate the finding of featured pathway(s) of KK01 differentiated from the established drugs. Comparison of drug target(s) between KK01 and DG can help to understand the synergistic effects of multiple constituents in the herb. |
Institute | University of North Carolina |
Department | Systems and Translational Sciences |
Laboratory | Sumner Lab |
Last Name | Sumner |
First Name | Susan |
Address | Eastern Regional Comprehensive Metabolomics Resource Core, UNC Nutrition Research Institute, 500 Laureate Way, Kannapolis, NC, 28081 |
susan_sumner@unc.edu | |
Phone | 704-250-5066 |
Submit Date | 2016-12-30 |
Num Groups | 10 |
Total Subjects | 93 samples for positive mode and 80 samples for negative mode |
Raw Data Available | Yes |
Raw Data File Type(s) | raw(Thermo) |
Analysis Type Detail | LC-MS |
Release Date | 2018-02-07 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Factors:
Subject type: Serum; Subject species: Mus musculus (Factor headings shown in green)
mb_sample_id | local_sample_id | Gene type | Phenotypic grouping and treaments |
---|---|---|---|
SA027878 | S_53 | C57BLKsJ-db/db | Group1, DG extract high dose |
SA027879 | S_60 | C57BLKsJ-db/db | Group1, DG extract high dose |
SA027880 | S_47 | C57BLKsJ-db/db | Group1, DG extract high dose |
SA027881 | S_56 | C57BLKsJ-db/db | Group1, DG extract high dose |
SA027882 | S_67 | C57BLKsJ-db/db | Group1, DG extract high dose |
SA027883 | S_7 | C57BLKsJ-db/db | Group1, DG extract high dose |
SA027884 | S_19 | C57BLKsJ-db/db | Group1, DG extract high dose |
SA027875 | S_28 | C57BLKsJ-db/db | Group1, DG extract high dose |
SA027876 | S_34 | C57BLKsJ-db/db | Group1, DG extract high dose |
SA027877 | S_42 | C57BLKsJ-db/db | Group1, DG extract high dose |
SA027813 | S_3 | C57BLKsJ-db/db | Group 2, DG extract low dose |
SA027814 | S_36 | C57BLKsJ-db/db | Group 2, DG extract low dose |
SA027815 | S_57 | C57BLKsJ-db/db | Group 2, DG extract low dose |
SA027816 | S_38 | C57BLKsJ-db/db | Group 2, DG extract low dose |
SA027817 | S_54 | C57BLKsJ-db/db | Group 2, DG extract low dose |
SA027818 | S_25 | C57BLKsJ-db/db | Group 2, DG extract low dose |
SA027819 | S_77 | C57BLKsJ-db/db | Group 2, DG extract low dose |
SA027820 | S_4 | C57BLKsJ-db/db | Group 2, DG extract low dose |
SA027821 | S_16 | C57BLKsJ-db/db | Group 2, DG extract low dose |
SA027822 | S_73 | C57BLKsJ-db/db | Group 2, DG extract low dose |
SA027823 | S_33 | C57BLKsJ-db/db | Group 3, KK 01 high dose |
SA027824 | S_76 | C57BLKsJ-db/db | Group 3, KK 01 high dose |
SA027825 | S_51 | C57BLKsJ-db/db | Group 3, KK 01 high dose |
SA027826 | S_5 | C57BLKsJ-db/db | Group 3, KK 01 high dose |
SA027827 | S_61 | C57BLKsJ-db/db | Group 3, KK 01 high dose |
SA027828 | S_48 | C57BLKsJ-db/db | Group 3, KK 01 high dose |
SA027829 | S_20 | C57BLKsJ-db/db | Group 3, KK 01 high dose |
SA027830 | S_15 | C57BLKsJ-db/db | Group 3, KK 01 high dose |
SA027831 | S_59 | C57BLKsJ-db/db | Group 3, KK 01 high dose |
SA027832 | S_66 | C57BLKsJ-db/db | Group 3, KK 01 high dose |
SA027833 | S_79 | C57BLKsJ-db/db | Group 4, KK 01 low dose (i.p.) |
SA027834 | S_23 | C57BLKsJ-db/db | Group 4, KK 01 low dose (i.p.) |
SA027835 | S_14 | C57BLKsJ-db/db | Group 4, KK 01 low dose (i.p.) |
SA027836 | S_82 | C57BLKsJ-db/db | Group 4, KK 01 low dose (i.p.) |
SA027837 | S_50 | C57BLKsJ-db/db | Group 4, KK 01 low dose (i.p.) |
SA027838 | S_29 | C57BLKsJ-db/db | Group 4, KK 01 low dose (i.p.) |
SA027839 | S_37 | C57BLKsJ-db/db | Group 4, KK 01 low dose (i.p.) |
SA027840 | S_43 | C57BLKsJ-db/db | Group 4, KK 01 low dose (i.p.) |
SA027841 | S_39 | C57BLKsJ-db/db | Group 4, KK 01 low dose (i.p.) |
SA027842 | S_12 | C57BLKsJ-db/db | Group 4, KK 01 low dose (i.p.) |
SA027843 | S_44 | C57BLKsJ-db/db | Group 5, metformin |
SA027844 | S_71 | C57BLKsJ-db/db | Group 5, metformin |
SA027845 | S_13 | C57BLKsJ-db/db | Group 5, metformin |
SA027846 | S_75 | C57BLKsJ-db/db | Group 5, metformin |
SA027847 | S_58 | C57BLKsJ-db/db | Group 5, metformin |
SA027848 | S_49 | C57BLKsJ-db/db | Group 5, metformin |
SA027849 | S_1 | C57BLKsJ-db/db | Group 5, metformin |
SA027850 | S_74 | C57BLKsJ-db/db | Group 5, metformin |
SA027851 | S_8 | C57BLKsJ-db/db | Group 5, metformin |
SA027852 | S_46 | C57BLKsJ-db/db | Group 6, rosiglitazone |
SA027853 | S_18 | C57BLKsJ-db/db | Group 6, rosiglitazone |
SA027854 | S_52 | C57BLKsJ-db/db | Group 6, rosiglitazone |
SA027855 | S_2 | C57BLKsJ-db/db | Group 6, rosiglitazone |
SA027856 | S_45 | C57BLKsJ-db/db | Group 6, rosiglitazone |
SA027857 | S_69 | C57BLKsJ-db/db | Group 6, rosiglitazone |
SA027858 | S_21 | C57BLKsJ-db/db | Group 6, rosiglitazone |
SA027859 | S_32 | C57BLKsJ-db/db | Group 6, rosiglitazone |
SA027860 | S_65 | C57BLKsJ-db/db | Group 6, rosiglitazone |
SA027861 | S_72 | C57BLKsJ-db/db | Group 6, rosiglitazone |
SA027862 | S_68 | C57BLKsJ-db/db | Group 7, saline |
SA027863 | S_70 | C57BLKsJ-db/db | Group 7, saline |
SA027864 | S_22 | C57BLKsJ-db/db | Group 7, saline |
SA027865 | S_41 | C57BLKsJ-db/db | Group 7, saline |
SA027866 | S_24 | C57BLKsJ-db/db | Group 7, saline |
SA027867 | S_64 | C57BLKsJ-db/db | Group 7, saline |
SA027868 | S_40 | C57BLKsJ-db/db | Group 7, saline |
SA027869 | S_27 | C57BLKsJ-db/db | Group 7, saline |
SA027870 | S_62 | C57BLKsJ-db/db | Group 7, saline |
SA027871 | S_35 | C57BLKsJ-db/db | Group 8, saline |
SA027872 | S_81 | C57BLKsJ-db/db | Group 9, saline (i.p.) |
SA027873 | S_83 | C57BLKsJ-db/db | Group 9, saline (i.p.) |
SA027874 | S_10 | C57BLKsJ-db/db | Group 9, saline (i.p.) |
SA027803 | S_55 | C57BLKsJ (WT) | Group 8, saline |
SA027804 | S_9 | C57BLKsJ (WT) | Group 8, saline |
SA027805 | S_17 | C57BLKsJ (WT) | Group 8, saline |
SA027806 | S_30 | C57BLKsJ (WT) | Group 8, saline |
SA027807 | S_78 | C57BLKsJ (WT) | Group 8, saline |
SA027808 | S_11 | C57BLKsJ (WT) | Group 8, saline |
SA027809 | S_26 | C57BLKsJ (WT) | Group 8, saline |
SA027810 | S_80 | C57BLKsJ (WT) | Group 8, saline |
SA027811 | S_63 | C57BLKsJ (WT) | Group 8, saline |
SA027812 | S_6 | C57BLKsJ (WT) | Group 8, saline |
SA027885 | P_8 | Pool serum from Sigma | - |
SA027886 | P_9 | Pool serum from Sigma | - |
SA027887 | P_11 | Pool serum from Sigma | - |
SA027888 | P_7 | Pool serum from Sigma | - |
SA027889 | P_10 | Pool serum from Sigma | - |
SA027890 | P_2 | Pool serum from Sigma | - |
SA027891 | P_1 | Pool serum from Sigma | - |
SA027892 | P_3 | Pool serum from Sigma | - |
SA027893 | P_4 | Pool serum from Sigma | - |
SA027894 | P_5 | Pool serum from Sigma | - |
SA027895 | P_6 | Pool serum from Sigma | - |
Showing results 1 to 93 of 93 |